Molecular Diagnostics For Sexually Transmitted Diseases Global Market Report 2025

Description

Molecular diagnostics for sexually transmitted diseases (STDs) involve methods that detect the genetic material, DNA or RNA of infectious agents to confirm the presence of pathogens. These techniques are highly accurate and sensitive, allowing detection even in asymptomatic cases. By analyzing the molecular structure of pathogens, these diagnostics ensure reliable identification, supporting faster and more precise diagnosis.

The primary product categories for molecular diagnostics of STDs include instruments and services, consumables, and software. Instruments comprise the diagnostic devices and platforms used for pathogen detection, while services cover laboratory testing, sample processing, and interpretation of diagnostic results provided by healthcare or diagnostic companies. These diagnostics employ various technologies, including laboratory-based testing and point-of-care testing, and are used in a range of applications such as testing for chlamydia trachomatis (CT), neisseria gonorrhoeae (NG), syphilis, gonorrhea, herpes simplex virus (HSV), human papillomavirus (HPV), human immunodeficiency virus (HIV), trichomonas, ureaplasma, mycoplasma, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The molecular diagnostics for sexually transmitted diseases market research report is one of a series of new reports from The Business Research Company that provides molecular diagnostics for sexually transmitted diseases market statistics, including the molecular diagnostics for sexually transmitted diseases industry global market size, regional shares, competitors with the molecular diagnostics for sexually transmitted diseases market share, detailed molecular diagnostics for sexually transmitted diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the molecular diagnostics for sexually transmitted diseases industry. This molecular diagnostics for sexually transmitted diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The molecular diagnostics for sexually transmitted diseases market size has grown rapidly in recent years. It will grow from $3.31 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth during the historic period can be credited to the rising prevalence of sexually transmitted infections, increased utilization of nucleic acid amplification tests, heightened awareness through government screening initiatives, backing from global health organizations, and early adoption by diagnostic laboratories.

The molecular diagnostics for sexually transmitted diseases market size is expected to see rapid growth in the next few years. It will grow to $5.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be ascribed to an increasing emphasis on early disease detection, rising demand for personalized diagnostics, expansion of sexually transmitted infection surveillance initiatives, growing public-private collaborations, and a greater preference for non-invasive testing approaches. Key trends during this period include advancements in molecular assay technologies, innovations in point-of-care diagnostic devices, development of multiplex PCR-based testing panels, progress in portable and automated systems, and the integration of artificial intelligence for result interpretation.

The rising prevalence of sexually transmitted infections (STIs) is expected to drive growth in the molecular diagnostics for sexually transmitted diseases market. STIs are infections caused by bacteria, viruses, or parasites that are transmitted through sexual contact, affecting the reproductive and urinary systems. The increasing prevalence is largely attributed to inconsistent use of protection methods, which facilitates transmission among sexually active individuals. Molecular diagnostics enable early and accurate detection of pathogens, including in asymptomatic cases, allowing timely treatment, reducing disease spread, and improving patient outcomes. For example, according to the National Association of County and City Health Officials (NACCHO), a US-based nonprofit, a total of 3,755 congenital syphilis cases were reported in January 2024, representing a 31% increase between 2021 and 2022. This growing prevalence is therefore propelling the molecular diagnostics for STDs market.

Key companies in this market are focusing on innovations such as rapid point-of-care polymerase chain reaction (PCR) devices to enhance diagnostic speed, accuracy, and accessibility. These portable devices combine sample preparation, amplification, and detection in a single unit, enabling sensitive pathogen detection outside traditional labs. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women's Sexual Health Test. This single-use, handheld PCR device identifies chlamydia, gonorrhea, and trichomoniasis from vaginal samples in 30 minutes without external instrumentation or cold-chain logistics. Authorized for prescription home use, it represents the first FDA-cleared molecular diagnostic test for multiple STIs usable outside clinical settings, reflecting the trend toward decentralized, accessible testing.

In December 2024, OraSure Technologies, a US-based provider of point-of-care and home diagnostic solutions, acquired Sherlock Biosciences. This acquisition expanded OraSure's molecular diagnostics portfolio in sexual health by integrating Sherlock's over-the-counter chlamydia and gonorrhea self-test, which delivers lab-quality results in under 30 minutes using CRISPR- and isothermal amplification-based platforms. Sherlock Biosciences specializes in molecular diagnostics for sexually transmitted infections.

Major players in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMerieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the molecular diagnostics for sexually transmitted diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The molecular diagnostics for sexually transmitted diseases market consists of revenues earned by entities by providing services such as test development, sample collection, nucleic acid amplification, and point of care diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The molecular diagnostics for sexually transmitted diseases market also includes sales of polymerase chain reaction kits, isothermal nucleic acid amplification kits, clustered regularly interspaced short palindromic repeats-based tests, and instrument-free molecular diagnostic systems. values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Molecular Diagnostics For Sexually Transmitted Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on molecular diagnostics for sexually transmitted diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for molecular diagnostics for sexually transmitted diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The molecular diagnostics for sexually transmitted diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Instruments And Services; Consumables; Software
2) By Technology: Laboratory Testing; Point-Of-Care Testing
3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing; Syphilis Testing; Gonorrhea Testing; Herpes Simplex Virus (HSV) Testing; Human Papillomavirus (HPV) Testing; Human Immunodeficiency Virus (HIV) Testing; Trichomonas; Ureaplasma And Mycoplasma; Other Applications
Subsegment:
1) By Instruments And Services: Molecular Diagnostic Analyzers; Automated Polymerase Chain Reaction Systems; Nucleic Acid Extraction Instruments; Diagnostic Service Providers; Maintenance And Calibration Services; Installation And Training Services
2) By Consumables: Deoxyribonucleic Acid Extraction Kits; Ribonucleic Acid Extraction Kits; Polymerase Chain Reaction Reagents; Nucleic Acid Probes; Control And Reference Standards; Detection Enzymes And Buffers
3) By Software: Data Interpretation And Reporting Software; Polymerase Chain Reaction Workflow Management Software; Laboratory Information Management Systems; Diagnostic Decision Support Software; Quality Control Monitoring Software
Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Illumina Inc.; Hologic Inc.; bioMerieux S.A.; QuidelOrtho Corporation; QIAGEN N.V.; Cepheid; Sansure Biotech Inc.; OraSure Technologies Inc.; Meridian Bioscience; Seegene Inc.; Visby Medical Inc.; Zeesan Biotech; Binx Health Inc.; GCC Biotech; GeneProof; Solone Life Sciences India (P) Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37822

1. Executive Summary

2. Molecular Diagnostics For Sexually Transmitted Diseases Market Characteristics

3. Molecular Diagnostics For Sexually Transmitted Diseases Market Trends And Strategies

4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Molecular Diagnostics For Sexually Transmitted Diseases Growth Analysis And Strategic Analysis Framework

5.1. Global Molecular Diagnostics For Sexually Transmitted Diseases PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Growth Rate Analysis
5.4. Global Molecular Diagnostics For Sexually Transmitted Diseases Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Molecular Diagnostics For Sexually Transmitted Diseases Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Molecular Diagnostics For Sexually Transmitted Diseases Total Addressable Market (TAM)

6. Molecular Diagnostics For Sexually Transmitted Diseases Market Segmentation

6.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Instruments And Services
Consumables
Software
6.2. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Laboratory Testing
Point-Of-Care Testing
6.3. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing
Syphilis Testing
Gonorrhea Testing
Herpes Simplex Virus (HSV) Testing
Human Papillomavirus (HPV) Testing
Human Immunodeficiency Virus (HIV) Testing
Trichomonas
Ureaplasma And Mycoplasma
Other Applications
6.4. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Instruments And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Molecular Diagnostic Analyzers
Automated Polymerase Chain Reaction Systems
Nucleic Acid Extraction Instruments
Diagnostic Service Providers
Maintenance And Calibration Services
Installation And Training Services
6.5. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Deoxyribonucleic Acid Extraction Kits
Ribonucleic Acid Extraction Kits
Polymerase Chain Reaction Reagents
Nucleic Acid Probes
Control And Reference Standards
Detection Enzymes And Buffers
6.6. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Softwares, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Data Interpretation And Reporting Software
Polymerase Chain Reaction Workflow Management Software
Laboratory Information Management Systems
Diagnostic Decision Support Software
Quality Control Monitoring Software

7. Molecular Diagnostics For Sexually Transmitted Diseases Market Regional And Country Analysis

7.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market

8.1. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Molecular Diagnostics For Sexually Transmitted Diseases Market

9.1. China Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
9.2. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Molecular Diagnostics For Sexually Transmitted Diseases Market

10.1. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market

11.1. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
11.2. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market

12.1. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market

13.1. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market

14.1. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
14.2. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market

15.1. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
15.2. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Molecular Diagnostics For Sexually Transmitted Diseases Market

16.1. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market

17.1. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Molecular Diagnostics For Sexually Transmitted Diseases Market

18.1. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market

19.1. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market

20.1. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market

21.1. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
21.2. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market

22.1. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Molecular Diagnostics For Sexually Transmitted Diseases Market

23.1. North America Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
23.2. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Molecular Diagnostics For Sexually Transmitted Diseases Market

24.1. USA Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
24.2. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market

25.1. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
25.2. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Molecular Diagnostics For Sexually Transmitted Diseases Market

26.1. South America Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
26.2. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market

27.1. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market

28.1. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
28.2. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market

29.1. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
29.2. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Landscape And Company Profiles

30.1. Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Landscape
30.2. Molecular Diagnostics For Sexually Transmitted Diseases Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Molecular Diagnostics For Sexually Transmitted Diseases Market Other Major And Innovative Companies

31.1. Hologic Inc.
31.2. bioMerieux S.A.
31.3. QuidelOrtho Corporation
31.4. QIAGEN N.V.
31.5. Cepheid
31.6. Sansure Biotech Inc.
31.7. OraSure Technologies Inc.
31.8. Meridian Bioscience
31.9. Seegene Inc.
31.10. Visby Medical Inc.
31.11. Zeesan Biotech
31.12. Binx Health Inc.
31.13. GCC Biotech
31.14. GeneProof
31.15. Solone Life Sciences India (P) Ltd.

32. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Molecular Diagnostics For Sexually Transmitted Diseases Market

34. Recent Developments In The Molecular Diagnostics For Sexually Transmitted Diseases Market

35. Molecular Diagnostics For Sexually Transmitted Diseases Market High Potential Countries, Segments and Strategies

35.1 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Countries Offering Most New Opportunities
35.2 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Segments Offering Most New Opportunities
35.3 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer